Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer

Bo Jan Noordman joins The Lancet Oncology to discuss the findings from his study of residual disease detection in oesophageal cancer. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv